MEDICA Press Release - SUTUREGARD® ISR Retention Suture Device
X

SUTUREGARD® Medical, Inc. Blog

 

SUTUREGARD® Medical, Inc is pleased to announce that it will be presenting at the MEDICA International Trade Fair. The fair, which runs from 18 to 21 November in Düsseldorf, Germany, will present a platform for more than 5,000 exhibitors to display innovative products and ideas. It is a vital opportunity for the company to showcase the SUTUREGARD® ISR Retention Suture Device, a patented technology that aids in surgical closure of high-tension wounds through rapid tissue expansion.

"Our goal at MEDICA 2019 is to forge relationships with international distribution partners. We thank the Business Oregon Export Promotion grant fund and our packaging and sterilization partner, DemeTECH for making this trip possible", says Jen Akeroyd, COO & Chair. The MEDICA fair brings together the world of medical technology for insights into the current and future state of technological equipment. This opportunity is in line with the company's long-term goal of becoming the world leader in RITE and eventually, a recognized brand that deals with wound closure technology.

The SUTUREGARD® ISR Retention Suture Device reduces skin tension on a wounded area to enable surgical closure. The device stretches skin safely to allow closure using surgical methods. It also serves as an alternative for repairing wounds on fragile skin. The SUTUREGARD® ISR Retention Suture Device enables less traumatic wound repairs and decreases wound healing complications.

Surgeons who have used the device have seen a 95% decrease in the rate of scalp flaps or grafts. Compared to similar devices in the market, the SUTUREGARD® ISR Retention Suture Device is gentler on the skin. This is because it makes fewer punctures on the skin.

SUTUREGARD™ Medical, Inc is a private firm based in Portland, Oregon that has developed patented technology for surgeons to perform simple closure of high-tension wounds while causing minimal trauma and reducing the healing period. It is funded by the Oregon State University Venture Development Fund as well as private equity.

The company spent three years on research, customer discovery and clinical studies prior to launching the device. The result of these efforts was the innovative device that uses Rapid Interoperative Tissue Expansion (RITE) to help surgeons in quickly stretching skin during surgery. The SUTUREGARD® ISR Retention Suture Device had a successful sales launch and has since been issued with US patent 10,064,616 and four pending patents. SUTUREGARD™ Medical, Inc is proud to be behind this clinically and economically successful technology, and seeks to demonstrate the usefulness of RITE in various surgical disciplines.

Related

Press Release - Patient Self-Removal of HEMIGARD During COVID Now Published

JAAD Case Reports recently published, “Use of a novel adhesive suture retention wound closure devic...

Read More >

Are Scalp Repairs Slowing You Down?

Skip the scalp flap or graft with the SUTUREGARD® Rapid Interaoperative Tissue Expansion (RITE) Devi...

Read More >

What is Squamous Cell Carcinoma (SCC)?

Squamous cell carcinoma (SCC) is the second most common skin cancer. While basal cell carcinoma (BCC...

Read More >

What is Basal Cell Carcinoma (BCC)?

A basal cell carcinoma (BCC) is one of the most common skin cancers. Every year, there are over 4 mi...

Read More >

Bill Lear, MD, Discusses Development of HEMIGARD ARS

Bill Lear, MD, Mohs surgeon now but 5-year emergency physician previously, talks with Dr. Mark Plast...

Read More >

Skin Flap Alternatives

We have previously discussed skin grafts and flaps (link to those posts). The major distinction in a...

Read More >

Prevent and Manage Wound Dehiscence.

Making wound closure easier for surgeons and better for patients.

Contact Us